Study reveals potential targets to improve the treatment of myeloma

A ground-breaking study by researchers from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS) has revealed crucial insights into the role of the histone methyltransferase NSD2 and its epigenetic target PKCα in causing t(4;14) translocated multiple myeloma (MM), a high-risk subtype of blood cancer, to be more aggressive and resistant to treatment.

‘I’m not safe here’: Schools ignore federal rules on restraint and seclusion

Photos show blood splattered across a small bare-walled room in a North Carolina school where a second grader repeatedly punched himself in the face in

January 17, 2024

Gene Therapy for Sickle Cell Disease Likely Cost-Effective if Under $2 Million

Compared with common care, gene therapy for sickle cell disease (SCD) would likely be cost-effective if its price was below $2 million, according to a

January 23, 2024

PharmAla Announces Private Placement | Psychedelic Invest

TORONTO, Dec. 13, 2024 (GLOBE NEWSWIRE) — PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the

December 13, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.